sponsored content

DuPont, Eurofins develop probiotic testing capability

20 Jul 2018

DuPont Nutrition & Health and Eurofins have developed and validated strain-level identification assays in probiotic testing, leading the way for industry-wide product integrity and label accuracy.

DuPont, Eurofins develop probiotic testing capability

DuPont Nutrition & Health and Eurofins have developed and validated strain-level identification assays in probiotic testing, leading the way for industry-wide product integrity and label accuracy.

DuPont says it routinely utilises new technologies to improve its methods of strain identification. Eurofins will employ DuPont’s polymerase-chain-reaction (PCR) genotyping assays to identify probiotics at the strain level in both raw materials and finished products.

The need for strain-specific testing is clear, Dupont believes, noting that numerous studies have found inaccuracies in probiotic labelling, with issues including incorrect taxonomy, missing species and unlabelled species.

“These findings emphasise the necessity of reliable methods to determine the taxonomy of microbial populations in probiotic products,” said Wesley Morovic, scientist in the Genomics & Microbiome Science group at DuPont Nutrition & Health. “However, because strain identification has not historically been required, little investment has been made to support the industry in doing so. DuPont is one of few manufacturers to share its genetic identification methods with customers and the public.”

By making its genotyping PCRs available and working with Eurofins to develop accurate tests, DuPont claims it is leading the industry toward label traceability.

“Many manufacturers understand that verifying raw materials and identifying finished products is as important as quantifying potency, for both label compliance and manufacturer confidence,” said Mehgan Styke, business development manager at Eurofins. “But until now, the tools for specific and accurate identification were either inaccessible or had yet to be developed; adding to the challenge are the nuances of probiotic products. With DuPont’s strain assays, Eurofins has become the first third-party laboratory to support identification to strain level, completing our portfolio of accurate testing for full label verification of potency, stability and identification.”

“Our goal is to use science-driven solutions to bring a higher level of transparency to the probiotics market,” said Megan DeStefano, global marketing manager, Probiotics, DuPont Nutrition & Health, “benefiting both manufacturers, who are under increased pressure to identify strains and are able to make health claims associated with specific ones, and consumers. We have worked closely with Eurofins to develop this service and are fully confident in their capabilities.”

“These methods are at a cost and efficiency in line with the current less accurate and less specific methods,” said Michael Drozd, president of Eurofins AgBio. “We are excited to leverage the collective knowledge of DuPont and Eurofins BioDiagnostics to bring the industry to a higher level of transparency.”

Related news

Our most-read articles of 2025

Our most-read articles of 2025

23 Dec 2025

From trade tariffs to heavy metals in protein, we look back at some of the industry’s highlights of 2025 and round up our most-read stories of the year.

Read more 
Bigging up bean-based products and consumption in Britain

Bigging up bean-based products and consumption in Britain

19 Dec 2025

Non-profit organisation the Food Foundation has launched a campaign, “Bang in Some Beans”, designed to increase UK consumers’ legume consumption.

Read more 
Ingredient transparency key to success in European natural health market

Ingredient transparency key to success in European natural health market

12 Dec 2025

Europe’s $40.7 billion supplements market is growing fast, fuelled by demand for products that support healthy ageing, mental wellbeing, and preventive health, say experts.

Read more 
Whole Foods Market forecasts fibre frenzy for 2026

Whole Foods Market forecasts fibre frenzy for 2026

11 Dec 2025

Whole Foods Market has released its top 2026 trends, predicting that a fibre frenzy will take place next year as health-conscious consumers seek out nutritious, filling options.

Read more 
Sorghum emerges as better-for-you hero ingredient

Sorghum emerges as better-for-you hero ingredient

9 Dec 2025

With the launch of Novak Djokovic’s sorghum-based brand, the grain’s popularity in the better-for-you snacking sphere is on the rise, thanks to its nutritional and sensory properties.

Read more 
Innovation promise in 'maturing' plant-based dairy alternatives market

Innovation promise in 'maturing' plant-based dairy alternatives market

8 Dec 2025

Plant-based dairy is a maturing market that still faces significant hurdles around taste, functionality, nutrition, and price, but industry is innovating fast, according to experts speaking at Fi Europe.

Read more 
Celebrating the winners of the Fi Europe Innovation Awards 2025

Celebrating the winners of the Fi Europe Innovation Awards 2025

3 Dec 2025

Food industry stakeholders celebrated as the winners of the Fi Europe Innovation Awards were announced at a ceremony in Paris.

Read more 
Apply now for the Vitafoods Europe Innovation Awards 2026!

Apply now for the Vitafoods Europe Innovation Awards 2026!

28 Nov 2025

Entries for the Vitafoods Europe Innovation Awards 2026 are now open! Game-changing companies have until 27 February to submit their entry across eight categories for the chance to win big.

Read more 
Concerns swirl around cinnamon’s compliance with EU law

Concerns swirl around cinnamon’s compliance with EU law

25 Nov 2025

Cinnamon may be a top functional ingredient, but it needs stronger protocols to ensure it meets EU food safety laws and quality standards, say researchers.

Read more 
Bone broth: From old-fashioned to en vogue

Bone broth: From old-fashioned to en vogue

24 Nov 2025

OXO’s entry into bone broth has turned the spotlight on this small but high-performance category – and there is still scope for growth, especially in the area of GLP-1 support.

Read more